Karyopharm Therapeutics’ (KPTI) Outperform Rating Reaffirmed at Royal Bank of Canada

Karyopharm Therapeutics (NASDAQ:KPTI)‘s stock had its “outperform” rating reiterated by investment analysts at Royal Bank of Canada in a report released on Monday,Benzinga reports. They presently have a $3.00 target price on the stock. Royal Bank of Canada’s target price would indicate a potential upside of 360.12% from the stock’s previous close.

Other equities analysts also recently issued research reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday, January 15th. StockNews.com downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. Finally, Piper Sandler lifted their target price on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $5.00.

Karyopharm Therapeutics Stock Performance

KPTI stock traded up $0.02 during mid-day trading on Monday, hitting $0.65. The company had a trading volume of 530,055 shares, compared to its average volume of 758,905. The firm has a market cap of $82.28 million, a PE ratio of -0.57 and a beta of 0.06. Karyopharm Therapeutics has a 12 month low of $0.58 and a 12 month high of $1.70. The stock’s fifty day moving average price is $0.69 and its two-hundred day moving average price is $0.78.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP increased its position in Karyopharm Therapeutics by 80.6% during the 3rd quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock valued at $1,474,000 after purchasing an additional 792,283 shares during the period. Geode Capital Management LLC increased its position in Karyopharm Therapeutics by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,355,392 shares of the company’s stock valued at $1,125,000 after purchasing an additional 43,856 shares during the period. AQR Capital Management LLC increased its position in Karyopharm Therapeutics by 494.5% during the 2nd quarter. AQR Capital Management LLC now owns 748,020 shares of the company’s stock valued at $649,000 after purchasing an additional 622,194 shares during the period. FMR LLC increased its position in Karyopharm Therapeutics by 26.1% during the 3rd quarter. FMR LLC now owns 369,723 shares of the company’s stock valued at $307,000 after purchasing an additional 76,510 shares during the period. Finally, Exchange Traded Concepts LLC increased its position in Karyopharm Therapeutics by 34.9% during the 3rd quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock valued at $182,000 after purchasing an additional 56,613 shares during the period. 66.44% of the stock is owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).